All In MedTech

FDA Clearance Tracker · P190032-S016

FoundationOne®Liquid CDx (F1LCDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 30, 2024

Approved

Time to decision

255 days

Received Dec 19, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P190032-S016
Device name
FoundationOne®Liquid CDx (F1LCDx)
Applicant location
Boston, MA
Received
Dec 19, 2023
Decided
Aug 30, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval order to expand the intended use of FoundationOne CDx (F1CDx) (P170019/S052) and FoundationOne Liquid CDx (F1LCDx) (P190032/S016) to include a companion diagnostic indication to identify patients with prostate cancer with BRCA1/2 alterations for the treatment with LYNPARZA (olaparib) in combination with abiraterone.

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.